Yes, Zepbound Is Approved for Weight Loss
Zepbound (tirzepatide) is FDA-approved specifically for chronic weight management in adults with obesity or overweight with weight-related conditions like high blood pressure, type 2 diabetes, or high cholesterol.[1] It's not for cosmetic weight loss but targets significant, sustained reduction in adults who meet clinical criteria.
How Zepbound Works for Weight Loss
Zepbound mimics two hormones—GLP-1 and GIP—that regulate blood sugar and appetite. Injected weekly, it slows digestion, reduces hunger, and promotes fullness, leading to 15-20% average body weight loss in trials (vs. 2-3% with placebo).[1][2] Doses start at 2.5 mg and go up to 15 mg.
Zepbound vs. Mounjaro: Same Drug, Different Labels
Zepbound and Mounjaro both contain tirzepatide from Eli Lilly. Mounjaro is approved for type 2 diabetes; Zepbound is for weight loss only. Off-label use of Mounjaro for weight loss is common but not FDA-endorsed for that purpose.[1]
Who Qualifies and How to Get It
Eligible patients have BMI ≥30 (obesity) or ≥27 with comorbidities. Prescriptions require in-person evaluation; telehealth options exist but face insurance hurdles. It's not for underweight individuals or short-term use.[1][3]
Common Side Effects Patients Report
Nausea, diarrhea, vomiting, and constipation affect up to 20-30% initially but often fade. Rare risks include pancreatitis, gallbladder issues, or thyroid tumors (seen in rodents).[1] Patients ask about 'Ozempic face' (facial sagging from rapid fat loss), mitigated by gradual dosing.
Cost, Coverage, and Savings Options
List price is $1,060/month without insurance. Medicare covers it for obesity in some cases; private plans vary (e.g., 50% cover post-2024 updates). Lilly's savings card cuts copays to $25 for eligible insured patients.[3]
When Does Zepbound's Patent Expire?
Key U.S. patents on tirzepatide expire in 2036, with formulation patents to 2041. Challenges from generics like those from Hims & Hers are ongoing, but no approvals yet.[4]
[1]: FDA.gov - Zepbound Approval Label (https://www.fda.gov/drugs/postmarket-drug-safety-information-patients-and-providers/zepbound-tirzepatide-injection)
[2]: NEJM - Tirzepatide Trials (https://www.nejm.org/doi/full/10.1056/NEJMoa2206038)
[3]: EliLilly.com - Zepbound Access (https://zepbound.lilly.com/)
[4]: DrugPatentWatch.com - Tirzepatide Patents (https://www.drugpatentwatch.com/p/tradename/ZEPBOUND)